F.D.A. Moves To Rein In Pain Killers The F.D.A. moves to rein in America’s huge usage of powerful painkillers. We’ll look at where they’re drawing the line.

read here

Some Important FACT! re: pharma marketing settlements

The recent slew of pharma marketing settlements with the Department of Justice goes to show that there's room for improvement when it comes to curbing dishonest advertising. Over the past decade, drugmakers have agreed to pay close to $14 billion in penance for off-label and safety-related claims. But for some companies, those settlements haven't deterred repeat misbehavior. Pfizer ($PFE), for one, has wrapped two marketing settlements for north of $400 million: one in 2004 totaling $430 million for promotions of seizure drug Neurotonin, and another in 2009 worth $2.3 billion--including a record-setting $1.3 billion in criminal penalties--over Bextra, Geodon, Zyvox and Lyrica.

Read more: UPDATED: FDA aims to train docs to spot misleading drug ads--and report them - FiercePharma http://www.fiercepharma.com/story/fda-aims-train-docs-spot-misleading-drug-ads-and-report-them/2013-10-29#ixzz2jDkkAhOu
Subscribe at FiercePharma

UPDATED: FDA aims to train docs to spot misleading drug ads--and report them October 29, 2013 | By Carly Helfand Read more: UPDATED: FDA aims to train docs to spot misleading drug ads--and report them - FiercePharma http://www.fiercepharma.com/story/fda-aims-train-docs-spot-misleading-drug-ads-and-report-them/2013-10-29#ixzz2jDk0EkQ0 Subscribe at FiercePharma

Third Question of the Day October 30, 2013 If you are traditional compounding pharmacy that does not wish or are financially able to become an outsourcing facility should you be looking to cut bait and SELL to a larger group like Mesa is selling to PAWS? Do you think the window of opportunity for selling will probably be a small one after federal compounding legislation passed?